IDEXX Laboratories stock
Price history
+0.39% over the period1 year: from $701.48 (November 13, 2025) to $704.23 (November 13, 2026), +0.39%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $704.23 |
| October 30, 2026 | $551.21 |
| September 30, 2026 | $522.19 |
| August 31, 2026 | $556.69 |
| July 31, 2026 | $559.07 |
| June 30, 2026 | $526.44 |
| May 29, 2026 | $563.53 |
| April 30, 2026 | $560.80 |
| March 31, 2026 | $561.89 |
| February 27, 2026 | $656.73 |
| January 30, 2026 | $670.46 |
| December 31, 2025 | $676.53 |
| November 28, 2025 | $752.88 |
| November 13, 2025 | $701.48 |
At a glance
The company
Develops, manufactures and distributes diagnostic products and software for companion animal, livestock, dairy and water testing markets
Latest results
Quarter to September 30, 2026 · EPS $4.01 (estimate $3.72)
Next event
TickerLandia's take on IDEXX Laboratories
- Priced as usual relative to earnings: P/E on the latest fiscal year 54 vs a median of 52 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 47 vs 36 (+30%) in a group of 9.
- Strong point: Profitability (90/100 in its group). Weak point: Financial strength (62/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−8.54% from the 52-week high
Analysts · 14 analysts
Average target$717.17+1.84% vs. price
Buy 9 · Hold 4 · Sell 1 · Buy
TickerLandia Fingerprint: IDEXX Laboratories
Compared with similar companies: very high profitability and very high price.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high88
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 33.6 90 P/E (trailing 12 months) 47.0 77 Price/sales 11.9 83 Forward P/E 41.7 98 Price/book 29.7 90 Profitabilityvery high90
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 62.7% 72 Net margin 25.4% 94 ROE 68.9% 91 ROA 26.7% 98 Operating margin 32.5% 94 Earnings stabilityhigh67
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 72 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthhigh62
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +8.52% 72 Revenue growth (year over year) +9.90% 61 Earnings growth (year over year) +17.90% 54 Financial strengthhigh62
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 35.0 87 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.26 82 Debt/equitycounts in reverse: lower means more financial strength 0.52 54 Current ratio 1.19 24 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong76
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (6 months) +31.14% 87 Distance from 200-day average +23.04% 90 Relative strength (3 months) +28.12% 97 1-year return +0.39% 31 Riskhigh65
How much the price swings.
Metric Value Position in group Volatility (60 days) 49.1% 76 Maximum drawdown (12 months) 34.2% 63 Beta (1 year) 0.83 57
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
IDEXX Laboratories is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), IDEXX Laboratories's P/E today is 53.8, in line with the median of its last 10 fiscal years (52.5; between 38.7 and 76.6 from 2016 to 2025). IDEXX Laboratories's P/E (trailing 12 months): 47.0, +30% against the median of a group of 9 similar companies (36.1).
Compared with 9 similar companies
| Metric | IDEXX Laboratories | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 47.0 | High | |
| Forward P/E | 41.7 | High | |
| Operating margin | 32.5% | High | |
| ROE | 68.9% | High | |
| Debt/equity | 0.52 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: IDEXX Laboratories. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.22B
Latest quarter · Q2 2026
Net income
$338.41M
Latest quarter · Q2 2026
Quarterly net margin
27.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $55.48B
- P/E
- 47.0
- EPS
- $14.97
- Volume
- 392.45K
- Daily trading
- €394.97M
- Dividend yield
- 0.00%
How IDEXX Laboratories is changing
All resultsRevenue grew 9.7% a year on average over the last 5 years
Operating margin rose from 26.7% to 31.6%
Profits turn into cash: free cash flow equal to 94% of net income
Returns
IDEXX Laboratories returns
$1,000 invested in IDEXX Laboratories 5 years ago, on November 15, 2021, would be worth $1,138 today: +13.78% in total, +2.62% per year. This is the price return only: dividends are excluded.
| Period | IDEXX Laboratories | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +35.35% | −3.12% | $1,353 |
| 6 months | +33.21% | +1.58% | $1,332 |
| Year to date | +4.09% | +10.46% | $1,041 |
| 1 year | +0.39% | +12.23% | $1,004 |
| 3 years | +62.87% | +71.41% | $1,629 |
| 5 years | +13.78% | +61.48% | $1,138 |
| 10 years | +544.31% | +249.40% | $6,443 |
Over the last 6 months it has done better than 71% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
IDEXX Laboratories: technical analysis
IDEXX Laboratories shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.1% below its all-time closing high ($766.68, November 25, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 72
- Above 70: a strong rise in a short time
- vs 200-session average
- +23.04%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since November 2, 2026
Support and resistance
Price areas where IDEXX Laboratories has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$704.23
- Support$661.21−6.11%4 touches, last on February 26, 2026
- Support$621.17−11.79%3 touches, last on August 4, 2026
- Support$602.13−14.50%3 touches, last on April 17, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.83
- Volatility (60 sessions, annualised)
- 49.1%
- Largest fall in the last year
- −34.17%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
IDEXX Laboratories: seasonality
Average monthly price change over 36 years
Over the last 36 years, the strongest month for IDEXX Laboratories has been February: +4.76% on average, positive in 22 years out of 35. The weakest has been March: −1.33% on average, positive in 19 years out of 35. November, the current month, has been positive in 22 years out of 35 (+2.82% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.94% | +2.60% | 20 of 35 |
| February | +4.76% | +2.29% | 22 of 35 |
| March | −1.33% | +1.68% | 19 of 35 |
| April | +4.42% | +4.15% | 26 of 35 |
| May | +2.35% | +1.61% | 22 of 35 |
| June | +0.48% | −1.47% | 16 of 35 |
| July | +4.76% | +6.10% | 24 of 36 |
| August | +1.50% | +0.42% | 18 of 36 |
| September | +1.33% | +0.28% | 20 of 36 |
| October | +0.83% | +2.65% | 19 of 36 |
| November | +2.82% | +2.97% | 22 of 35 |
| December | +2.69% | +2.35% | 20 of 35 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
IDEXX Laboratories and its competitors
Sales reach far beyond the United States, which accounts for 64% of revenue, while Europe, the Middle East and Africa represent 5.3%, and Germany, Canada, the United Kingdom, France and Australia each contribute between 2.6% and 4.8%. The company makes diagnostic instruments, test kits and reagents for veterinary clinics, livestock and poultry producers, dairy operations and water-testing laboratories. Its portfolio includes SNAP rapid test kits, blood and urine chemistry and hematology analyzers, and the Colilert family of tests for detecting total coliforms and E. coli in water.
- Headquarters
- Westbrook, United States
- Employees
- 11,000
- Founded
- 1983
- Chief executive
- Michael Erickson
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IDEXX LaboratoriesIDXX | $55.48B | 32.5% | 47.0 | +33.21% |
| Agilent TechnologiesA | $49.04B | 24.5% | 34.3 | +54.30% |
| NateraNTRA | $46.27B | -8.5% | — | +63.37% |
| IQVIA HoldingsIQV | $43.69B | 13.9% | 32.3 | +53.80% |
| Mettler-Toledo InternationalMTD | $34.59B | 27.8% | 37.7 | +69.56% |
| WatersWAT | $90.45B | 16.0% | 192.6 | +37.42% |
Same industry or related industries, similar size. Compare IDEXX Laboratories with its competitors · Full profile
More on IDEXX Laboratories
- IDEXX Laboratories revenue and financials
- IDEXX Laboratories valuation
- IDEXX Laboratories stock return
- IDEXX Laboratories employees, headquarters and business
